CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- 4 Open-market sale Chief Scientific Officer sold 30,000 shares at $16.28 ($488,298)
- 8-K Event Regulation FD disclosure
- 4 Open-market sale President and CEO sold 56,303 shares at $15.91 ($896,045)
- 4 Open-market sale Chief Financial Officer sold 12,823 shares at $15.55 ($199,335)
- 4 Open-market sale Chief Scientific Officer sold 27,165 shares at $15.71 ($426,803)
- 4 Option exercise Chief Scientific Officer acquired 76,250 shares (option exercise)
- 4 Option exercise Chief Financial Officer acquired 42,347 shares (option exercise)
- 4 Option exercise President and CEO acquired 132,679 shares (option exercise)
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market sale Chief Scientific Officer sold 383 shares at $12.68 ($4,857)
- 4 Open-market sale Chief Financial Officer sold 1,388 shares at $12.66 ($17,568)
- 4 Open-market sale President and CEO sold 3,595 shares at $12.66 ($45,513)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
Page 17 of 44 · 872 filings